Abemaciclib
Verzenio · CDK4/6 inhibitor
Benign creatinine rise via tubular secretion block.
PSEUDOPRE
MildOpen →
The Drug Explorer
Search the nephrotoxic landscape
A live index of 240+ anti-cancer agents, cross-filterable by injury signature, drug class, nephron segment, severity, and era. Profiled agents open to a full citation-grounded page; the rest are catalog entries with their signature kidney signal.
22 agents · filtered from 240
Profile
Adagrasib
Krazati · KRAS G12C inhibitor
Creatinine rise; emerging data.
PREGLOMATN
MildOpen →
Alectinib
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
PSEUDOPRE
MildOpen →
Bosutinib
Bosulif · BCR-ABL TKI
Reversible eGFR decline.
PSEUDOPRE
MildOpen →
Brigatinib
Alunbrig · ALK TKI
Creatinine elevation; usually benign.
PSEUDOPRE
MildOpen →
Capmatinib
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
PSEUDOPRE
MildOpen →
Ceritinib
Zykadia · ALK TKI
GI-driven prerenal AKI.
PSEUDOPRE
MildOpen →
Crizotinib
Xalkori · ALK/ROS1/MET TKI
Reversible creatinine rise and renal cysts.
RCYSTPSEUDOPRE
MildOpen →
Entrectinib
Rozlytrek · TRK/ROS1 TKI
Creatinine rise via reduced tubular secretion.
PSEUDOPRE
MildOpen →
Larotrectinib
Vitrakvi · TRK inhibitor
Mild creatinine rise; generally well tolerated.
PSEUDO
MildOpen →
Lorlatinib
Lorbrena · ALK TKI
Edema and metabolic effects.
PSEUDOPRELYTE
MildOpen →
Nilotinib
Tasigna · BCR-ABL TKI
eGFR decline over time.
PREHTNPSEUDO
MildOpen →
Olaparib
Lynparza · PARP inhibitor
Benign creatinine rise via OCT2/MATE inhibition.
PRETMAPSEUDO
MildOpen →
Palbociclib
Ibrance · CDK4/6 inhibitor
Generally renally well tolerated.
PSEUDOPRELYTE
MildOpen →
Repotrectinib
Augtyro · ROS1/TRK TKI
2023 ROS1 inhibitor; creatinine rise via secretion block.
PSEUDOPRELYTE
MildOpen →
Ribociclib
Kisqali · CDK4/6 inhibitor
Creatinine rise; QT prolongation.
PSEUDOPRELYTE
MildOpen →
Rucaparib
Rubraca · PARP inhibitor
Transporter-mediated creatinine rise.
PRELYTEPSEUDO
MildOpen →
Sotorasib
Lumakras · KRAS G12C inhibitor
Newer agent; renal data emerging.
PREATNPSEUDO
MildOpen →
Talazoparib
Talzenna · PARP inhibitor
Renally cleared; creatinine rise.
PREPSEUDO
MildOpen →
Tepotinib
Tepmetko · MET inhibitor
Creatinine rise and peripheral edema.
PSEUDOPRE
MildOpen →
Tucatinib
Tukysa · HER2 TKI
Benign creatinine rise via tubular secretion inhibition.
PSEUDOPRE
MildOpen →
Zongertinib
Hernexeos · HER2 TKI
HER2 exon20 TKI (2025); creatinine rise likely a secretion artifact.
PSEUDOPRE
MildOpen →